Apple
AAPL
Cisco
CSCO
Disney
DIS
4
Qualcomm
QCOM
5
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
DTIL Precision BioSciences
- 4.7700
- +0.0700+1.49%
Close Mar 31 16:00 ET
50.00MMarket Cap4.59P/E (TTM)
4.8600High4.2500Low86.36KVolume4.6500Open4.7000Pre Close395.51KTurnover0.99%Turnover Ratio4.59P/E (Static)10.48MShares14.660052wk High0.89P/B41.77MFloat Cap3.610052wk Low--Dividend TTM8.76MShs Float710.1060Historical High--Div YieldTTM12.98%Amplitude3.6100Historical Low4.5800Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Precision BioSciences Stock Forum
Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Positive
First-ever in vivo gene editing therapy cleared for Hepatitis B treatment globally
Successful initial clinical results with PBGENE-HBV showing substantial antiviral activity
Partner iECURE achieved complete clinical response in first infant treated for OTC deficiency
Strong cash position of $108.5M with runway into H2 2026
Negative
Revenu...
Breakthrough: First Infant Successfully Treated in iECURE's OTC Deficiency Gene Therapy Trial
iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
Friday, 21st March at 8:00 am
First participant dosed achieved complete clinical response per study protocol and data suggests partial restoration of functional OTC enzyme activity in the liver
iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus Elimination - Key Trial Updates
Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients
Preclinical data to be presented at the 2025 Muscular Dystrophy Association (MDA) - possible catalyst date 03/19/2025
*nfa
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class Pbgene-Hbv Designed to Eliminate Root Cause of Chronic Hepatitis B
No comment yet